William Blair Comments on Vistagen Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:VTGN)

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) – Investment analysts at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for shares of Vistagen Therapeutics in a report released on Wednesday, June 12th. William Blair analyst T. Lugo now anticipates that the company will post earnings per share of ($0.41) for the quarter, down from their previous estimate of ($0.38). The consensus estimate for Vistagen Therapeutics’ current full-year earnings is ($2.08) per share. William Blair also issued estimates for Vistagen Therapeutics’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.13) EPS and FY2026 earnings at ($1.27) EPS.

Vistagen Therapeutics Price Performance

Shares of VTGN opened at $3.52 on Friday. The company has a market capitalization of $95.11 million, a price-to-earnings ratio of -1.70 and a beta of 0.69. Vistagen Therapeutics has a 52 week low of $1.62 and a 52 week high of $24.71. The stock’s 50-day moving average price is $4.41 and its 200-day moving average price is $4.68.

Institutional Investors Weigh In On Vistagen Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Vistagen Therapeutics during the 4th quarter valued at about $48,000. Acadian Asset Management LLC acquired a new stake in Vistagen Therapeutics in the first quarter valued at approximately $169,000. AdvisorShares Investments LLC purchased a new stake in shares of Vistagen Therapeutics in the fourth quarter valued at approximately $279,000. Blair William & Co. IL acquired a new position in shares of Vistagen Therapeutics during the 3rd quarter worth approximately $446,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Vistagen Therapeutics during the 3rd quarter valued at approximately $726,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.